Stock Analysis
Novo-Nordisk A/SNVO
Sector: Healthcare · Industry: Drug Manufacturers - General
AnalystsHold36 analystsPrice is 12% of the way from the year's low to its high.
PMP Verdict
Insufficient financial data
No financial statements on file for this ticker — fundamental scores are not computed.
Bull Case
- ✓ROE 59.1% — efficient capital deployment
- ✓Interest coverage 149.1× — debt well covered
What's happening with NVO
About Novo-Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Show more
Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Employees: 69,500 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
Valuation
50CP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF13.3xA
Grade A: CheapPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield7.5%A
Grade A: ValueInverse of Finnhub P/FCF (own TTM FCF unavailable)
P/S (TTM)3.44xB
Grade B: FairPrice / TTM Revenue (own statements)
EV/EBITDA7.3xA
Grade A: CheapEnterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales3.7xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E11.5xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio4.82xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio-11.56A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield4.58%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio54.9%A
Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
50CROIC—
NOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE59.1%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA21.1%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin35.4%A
Grade A: HighNet Income / Revenue
Operating Margin—
TTM EBIT / TTM Revenue
Gross Margin80.7%A
Grade A: PremiumGross Profit / Revenue
FCF Margin—
FCF / Revenue
True FCF Margin—
TTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
0ERevenue CAGR—
Compound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue—
TTM stock-based comp / TTM Revenue
Financial Health
31DAltman Z-Score—
Bankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio0.87xD
Grade D: LowCurrent Assets/Liabilities
Quick Ratio0.66xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage149.1xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt Repayment—
Years to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity0.63xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Quality
0EPiotroski F-Score—
Financial strength 0–9. >7 Strong
Beneish M-Score—
Earnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability—
EBIT margin std deviation. Lower = stable
Capex / Revenue—
TTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.60xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
0EROIC >12% Years—
Share of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)—
Median annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years—
Share of completed fiscal years with positive free cash flow
Net Margin Floor—
Weakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$10.16
Cash & short-term investments per share (Finnhub)
Book Value / Share$50.00
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.—
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity—
Shareholders' equity (book value)
Asset / Liability—
Total Assets / Total Liabilities
Market
Market Cap$170.92B
Current Market Capitalization
Beta1.96D
Grade D: High volatilityPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Ratio snapshot Oct 17, 2026
Key Insights: Novo-Nordisk A/S (NVO)
NVO is down 0.99% at the last close. Return on equity of 59.1% is well above the market average.
- The stock currently yields 4.6% in dividends.
See how NVO ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all NVO moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Sep 21 | Pre-market | 41.14 | -4.86% | -2.17 |
| Sep 21 | Regular | 39.79 | -7.99% | -3.75 |
| Sep 21 | After-hours | 39.91 | -7.70% | -3.60 |
| Sep 17 | Regular | 43.36 | +3.94% | 2.27 |
Frequently Asked Questions about NVO
What is the current Novo-Nordisk A/S (NVO) stock price?
NVO is trading at $38.83 at the last market close, down 0.99% on the session. PreMarketPrice tracks NVO pre-market, intraday and after-hours prices.
Is NVO stock a buy right now?
PreMarketPrice's quantitative model rates Novo-Nordisk A/S's financial health at 31/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is NVO stock overvalued?
Novo-Nordisk A/S trades at a trailing P/E of n/a and our valuation score rates it 50/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Novo-Nordisk A/S report earnings?
No confirmed earnings date is currently scheduled for NVO. The Earnings section lists recent reports and updates as dates are announced.
What sector does Novo-Nordisk A/S operate in?
Novo-Nordisk A/S operates in the Healthcare sector, within the Drug Manufacturers - General industry. The Related Stocks section lists sector peers for comparison.
What does Novo-Nordisk A/S do?
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products.
About Novo-Nordisk A/S (NVO) Stock
Novo-Nordisk A/S (NVO) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry. As of the latest update, Novo-Nordisk A/S is trading at $38.83, down 0.99% on the day with a market capitalization of $170.9 billion. The financial health score for NVO is 31/100, which indicates weak financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for NVO stock.
NVO Stock Analysis & Key Metrics
On PreMarketPrice, you can track Novo-Nordisk A/S (NVO) across multiple dimensions:
- Pre-market price & movement: Real-time NVO stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for NVO with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Novo-Nordisk A/S across multiple reporting periods.
- Financial health score: A composite score of 31/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for NVO.
- Sector peers: Compare NVO against 4 other healthcare stocks on key financial metrics.
Is NVO a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Novo-Nordisk A/S (NVO) as an investment. The financial health score of 31/100 suggests weak financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Novo-Nordisk A/S (NVO) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.